Synthesis and biological evaluation of novel 1,2,3-benzotriazin-4-one derivatives as leukotriene A 4 hydrolase aminopeptidase inhibitors
摘要:
A series of novel 1,2,3-benzotriazin-4-one derivatives were designed, synthesized and their inhibitory activities against leukotriene A(4) hydrolase aminopeptidase in vitro were evaluated. Many compounds showed moderate to good activities at the concentration of 10 mu mol/L. Among them, compound IV-16 exhibited the highest inhibitory activity up to 80.6% with an IC50 of 1.30 +/- 0.20 mu mol/L. The compound IV-16 was also tested the proliferation inhibitory activities in THP1 human AML cell line and its binding model with LTA(4)H enzyme by molecular docking was studied. It indicated that 1,2,3-benzotriazin-4-one was a promising scaffold for further study. The relationship between structure and inhibitory activity was also preliminarily discussed. (C) 2016 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.
Auto-Tandem Catalysis with Ruthenium: From <i>o</i>
-Aminobenzamides and Allylic Alcohols to Quinazolinones <i>via</i>
Redox Isomerization/Acceptorless Dehydrogenation
作者:Weikang Zhang、Chong Meng、Yan Liu、Yawen Tang、Feng Li
DOI:10.1002/adsc.201800660
日期:2018.10.4
A strategy for the synthesis of quinazolinonesvia Ru‐catalyzed redoxisomerization/acceptorlessdehydrogenation was proposed and accomplished. In the presence of a commercially available [(p‐cymene)Cl2]2, a range of desirable products were obtained with o‐aminobenzamides and allylicalcohols as starting materials in moderate to high yields. This strategy is attractive due to high atom efficiency,
Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells
of 2-benzoylquinazolin-4(3H)-one skeleton was achieved successfully via the I2/DMSO catalytic system. A series of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-onederivatives was synthesized and evaluated for their cytotoxic activities against four cancer cell lines, HepG2, Bel-7402, A549, and U251. Among these compounds, 4a was the most effective one with IC50 values of 1.22 μM
肝细胞癌 (HCC) 是最常见的肝癌形式,也是全球癌症相关死亡的第四大原因。索拉非尼等一线药物对 HCC 患者仅提供适度的益处。在本研究中,通过I 2 /DMSO 催化体系成功实现了2-苯甲酰基喹唑啉-4(3 H )-one 骨架的克级合成。合成了一系列受 penipanoid C 启发的 2-(3,4,5-三甲氧基苯甲酰基)喹唑啉-4(3 H )-one 衍生物,并评估了它们对四种癌细胞系 HepG2、Bel-7402、A549、和U251。在这些化合物中,4a是最有效的一种,IC 50值为 1.22 μ M 和 1.71 μM 分别针对 HepG2 和 Bel-7402 细胞。机制研究表明,4a通过阻止细胞周期抑制肝细胞癌细胞增殖。此外,4a通过诱导活性氧的产生和提高凋亡相关蛋白的表达来诱导 HepG2 细胞凋亡。更重要的是,4a在 HepG2 异种移植模型中显示出显着的体内抗癌作